Propella Therapeutics

Propella Therapeutics, Inc. is dedicated to developing innovative first-class therapies with the aim of accelerating approval and reducing risks. Propella utilizes proven scientific technologies to create smarter, safer, and more effective products.Propella is a privately-held development-stage company focused on bringing improved versions of previously approved drugs to market. Propella’s lead candidate, topical CGS-200-5, is under development and has successfully completed a Phase 2 study for pain caused by knee osteoarthritis, with potential future use in the treatment of osteoarthritis (OA). PRL-02 is currently undergoing Investigational New Drug (IND) studies for prostate cancer and is expected to enter clinical development in 2021. PRL-01 has shown promising early results in late preclinical development for herpesvirus infections.